Global Anti-Asthmatics & COPD Drugs Market Outlook 2020-2030 - Featuring Novartis, GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca

The Business Research Company’s Anti-Asthmatics And Copd Drugs Market Report - Opportunities And Strategies - Global Forecast To 2030

Avail up to 50% off on ALL research reports at: https://www.thebusinessresearchcompany.com/global-market-reports Offer applies until Dec 31st

The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015, and is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023.Also the market is expected to growth to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%..

The Key drivers of the Anti-Asthmatics And COPD Drugs market include:-
Increased Incidence Of Tobacco Smoking – The increased use of tobacco led to a rise in tobacco related respiratory diseases such as COPD which in turn drove the anti-asthmatic and COPD drugs market during the historic period. While the global rate of smoking reduced, the increase in the population led to an increased number of smokers. The tobacco epidemic is a major public health issue globally and as of 2019, the annual number of deaths that could be attributed to tobacco related diseases was more than 8 million. In the UK, as of 2018, around 14.7% of population aged 18 years and above smoked cigarettes. Smoking continued to be popular in many regions, especially in Asia, Africa and the Middle East. Around 80% of the world`s 1.1 billion smokers lived in low- and middle-income countries. This trend increased the prevalence of chronic respiratory diseases, driving the market for anti-asthmatics and respiratory diseases.

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti-Asthmatics And COPD Drugs Market Segmentation:-
By Type Of Drug Class
1.Combination Drugs
2.Bronchodilators
3.Monoclonal Antibodies
4.Anti-Inflammatory Drugs

The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market by drug class, accounting for $14,964.9 million or 37.3% of the total market in 2019. The monoclonal antibodies market is expected to be the fastest-growing segment going forward at a CAGR of 7.4%.

By End Users
1.Asthma Patients
2.COPD Patients

The asthma patients was the largest segment of the anti-asthmatics and COPD drugs market by end user, accounting for $24,791.3 million or 61.7% of the total market in 2019. The COPD patients market is expected to be the fastest-growing segment going forward at a CAGR of 4.5%.

Request For A Sample Copy Of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2417&type=smp

By Geography - The Anti-Asthmatics And COPD Drugs market is segmented Into
1.North America
2.Western Europe
3.Asia Pacific
4.Eastern Europe
5.South America
6.Middle East
7.Africa

Place a DIRECT PURCHASE ORDER of the report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2417

Some of the major key players involved in the Anti-Asthmatics And COPD Drugs market are
1.GlaxoSmithKline plc
2.AstraZeneca plc
3.Boehringer Ingelheim GmbH
4.F. Hoffmann-La Roche Ltd.
5.Novartis AG

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.